For the Inventor, By the Inventor

Enter assignee name

Lebanon, NH, United States of America

Adimab, LLC

USPTO Granted Patents = 52

% Expired Patents = 5.8

EPO Patents = 11

Trademarks = 8

Forward Citations = 162

Loading Chart...

Loading Chart...

75 inventors (with patents filed for the assignee):

Laura M Walker (16 out of 24 patents)

Michael Feldhaus (14 out of 30 patents)

Maximiliano Vasquez (12 out of 69 patents)

4. Bianka Prinz (10 out of 61 patents)

5. Zhu Chen (8 out of 8 patents)

6. Kenneth Ellsworth (8 out of 9 patents)

7. James Milligan (8 out of 8 patents)

8. Elizabeth Oldham (8 out of 8 patents)

9. Dietmar Seiffert (8 out of 8 patents)

10. K Dane Wittrup (8 out of 28 patents)

11. Zachary A Bornholdt (7 out of 7 patents)

12. Larry Zeitlin (7 out of 7 patents)

13. Kartik Chandran (7 out of 20 patents)

14. Eric Krauland (7 out of 20 patents)

15. Anna Z Wec (7 out of 14 patents)

Core Competencies:

Antibodies

Anti-IL-27

Synthetic Antibody Libraries

Anti-Coagulation Factor XI

Chimeric Antigen Receptors

Polyclonal Mixtures

Monoclonal Antibodies

Polyspecificity Reagents

High Throughput Generation

Affinity Maturation

BACE1

T Cell Receptors

52 patents: Sort by Forward Citations

1. 12679892 - B7-H4 ANTIBODIES AND METHODS OF USE THEREOF (2026-07-14),

2. 12630624 - ANTI-IL-27 ANTIBODIES AND USES THEREOF (2026-05-19),

3. 12624105 - CHIMERIC ANTIGEN AND T CELL RECEPTORS AND METHODS OF USE (2026-05-12),

4. 12529164 - RATIONALLY DESIGNED, SYNTHETIC ANTIBODY LIBRARIES AND USES THEREFOR (2026-01-20),

5. 12281156 - Anti-respiratory syncytial virus antibodies, and methods of their generation and use (2025-04-21),

6. 12275800 - Anti-coagulation factor XI antibodies (2025-04-14),

7. 12258679 - Polyclonal mixtures of antibodies, and methods of making and using them (2025-03-25),

8. 12215141 - Anti-respiratory syncytial virus antibodies, and methods of their generation and use (2025-02-04),

9. 12209117 - Monoclonal antibodies and cocktails for treatment of Ebola infections (2025-01-28),

10. 12181480 - Polyspecificity reagents, methods for their preparation and use (2024-12-31),

11. 12180299 - Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use (2024-12-31),

12. 12018403 - Antibody libraries (2024-06-25),

13. 11746160 - Antibodies against BACE1 and use thereof for neural disease immunotherapy (2023-09-05),

14. 11661460 - Anti-coagulation factor XI antibodies (2023-05-30),

15. 11542330 - Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use (2023-01-03),

Company Overview

Adimab, LLC, based in Lebanon, NH, specializes in antibody engineering, focusing on the development of innovative therapeutic antibodies. The company is recognized for its expertise in creating synthetic antibody libraries and advancing technologies related to monoclonal antibodies, polyclonal mixtures, and polyspecificity reagents. Adimab's research encompasses various therapeutic areas, including anti-IL-27 and anti-coagulation factor XI, as well as chimeric antigen receptors, positioning it as a leader in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

52 Patents

#2 in Lebanon, NH

#50 in New Hampshire

#6,764 in US

#13,555 in the World

Lebanon, NH, United States of America

Adimab, LLC

Forward Citations = 162

75 inventors:

Laura M Walker (16 out of 24 patents)

Michael Feldhaus (14 out of 30 patents)

Maximiliano Vasquez (12 out of 69 patents)

4. Bianka Prinz (10 out of 61 patents)

5. Zhu Chen (8 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Adimab, LLC. Retrieved from https://idiyas.com/company/adimab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…